Llwytho...
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
BACKGROUND: High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combine...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Immunother Cancer |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6626404/ https://ncbi.nlm.nih.gov/pubmed/31300044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0655-4 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|